Recruiting
Phase 3

Zigakibart & Atrasentan

Sponsor:

Novartis Pharmaceuticals

Code:

NCT07850752

Conditions

IgA Nephropathy (IgAN)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

zigakibart

atrasentan

Placebo

Study Details

Brief summary:

This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of disease progression.

Conditions

IgA Nephropathy (IgAN)

Study ID

NCT07850752

Start date

Nov 11, 2026

Status verified date

Nov, 2026

Completion date

Dec 25, 2030

Anticipated

Primary completion date

Sep 17, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Aged ≥ 18 years at the time of signing the informed consent, prior to initiation of any study specific activities/procedures
  • Biopsy-proven IgAN diagnosed within the past 10 years prior to Screening, that, in the opinion of the Investigator, is not due to secondary causes. If a biopsy report within 10 years is not available, re-biopsy may be performed locally during Screening.
  • eGFR ≥ 30 mL/min/1.73m2 by a central laboratory at Screening, calculated using serum creatinine based on the 2021 CKD-EPI equation (Inker et al 2021)
  • UPCR ≥ 0.7 g/g (700 mg/g), as measured from a 24 hour urine collection by a central laboratory at Screening
  • Stable on a maximally tolerated dose of ACEi and/or ARB for at least 12 weeks prior to Screening unless intolerant to ACEi and ARB. May also be on a stable and well tolerated dose of SGLT2i, MRA, and/or GLP-1A if stable for at least 12 weeks prior to Screening. Participants are expected to stay on a stable dose of ACEi, ARB, SGLT2i, MRA and/or GLP-1A for the duration of the study.

Exclusion Criteria:

  • Chronic Kidney Disease (CKD), either clinically suspected or based on biopsy, resulting from any condition or another glomerulopathy/podocytopathy other than IgAN
  • Secondary forms of IgAN as determined by the Investigator, in the setting of systemic disorders, infections, autoimmune disorders or neoplasia
  • Diagnosis of active IgA vasculitis
  • Clinical suspicion of IgAN with rapidly progressive glomerulonephritis (RPGN) based on Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (2025)
  • Current clinical diagnosis of nephrotic syndrome
  • Known history of heart failure or conditions relating to fluid overload such as pulmonary edema, uncontrolled peripheral edema, pleural effusion, or ascites
  • Current severe infection requiring antimicrobials, or history of recurrent, severe infections as determined by the Investigator

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Enrollment

340 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: zigakibart + atrasentan

Patients receive zigakibart and atrasentan

active comparator: zigakibart + placebo

Patients receive zigakibart and matching placebo

Interventions

zigakibart

Solution for injection via PFS-NSD

atrasentan

Tablet

Placebo

Tablet

Primary outcome measure

  • Change in proteinuria from Baseline to Week 36, based on 24 hour urine collection [ Time Frame: Baseline, Week 36 ]

Central Contacts and Locations

Central contacts

Novartis Pharmaceuticals

+41613241111

Locations

Nephrology Consultants LLC

Recruiting

Huntsville, Alabama, United States, 35805

Contacts

Principal Investigator:

Michael Quadrini

West Coast Kidney Institute

Recruiting

Fremont, California, United States, 94538

Contacts

Principal Investigator:

Varun Chawla

Nephrology Associates PA

Recruiting

Newark, Delaware, United States, 19713

Contacts

Principal Investigator:

Theodore Saad

Florida Kidney Physicians

Recruiting

Riverview, Florida, United States, 33578

Contacts

Principal Investigator:

Amit Johnsingh

Florida Kidney Physicians LLC

Recruiting

Temple Terrace, Florida, United States, 33637

Contacts

Principal Investigator:

Wayne Robert Kotzker

Southeast Kidney Associates

Recruiting

East Point, Georgia, United States, 30344

Contacts

Principal Investigator:

Charmaine Emelife

DaVita Clinical Research

Recruiting

Las Vegas, Nevada, United States, 89146

Contacts

Principal Investigator:

Mark Vishnepolsky

Northern Assoc of Northern VA

Recruiting

Fairfax, Virginia, United States, 22033

Contacts

Principal Investigator:

Ahmadshah Mirkhel

More Information

Sponsor

Novartis Pharmaceuticals

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • Zigakibart
  • Atrasentan
  • IgA nephropathy
  • IgAN
  • Proteinuria
  • UPCR
  • eGFR
  • eGFR slope
  • Kidney function decline

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.